I am both humbled and excited to be part of Sparian Biosciences' groundbreaking project, funded by the recent UG3 grant (DA058553), which aims to address the pressing need for an FDA-approved treatment for psychostimulant use disorder. Working alongside Dr. Chris McCurdy, Jay McLaughlin, and Abhisheak Sharma, my role involves a detailed exploration of the pharmacodynamic properties of these dual-acting ligands. This work is a critical step toward progressing our lead molecule into Phase 1 clinical trials. It's a privilege to contribute to a project with the potential to make a significant difference in the lives of those struggling with psychostimulant use disorder. I look forward to sharing our journey and milestones.